Trial Profile
A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms EMPEROR-Reduced
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- 01 Dec 2023 Results of Pooled analysis investigating the effect of empagliflozin on serum markers of collagen turnover in patients enrolled in the EMPEROR-Preserved and EMPEROR-Reduced trials, published in the European Journal of Heart Failure.
- 14 Nov 2023 Results analyzing Growth differentiation factor 15 in serum samples from the EMPEROR-Reduced and EMPEROR-Preserved , published in the European Journal of Heart Failure
- 13 Nov 2023 Results assessing the the association of IGFBP-7 with risk of HF hospitalization or cardiovascular (CV) death and progression of renal disease in the EMPEROR-Reduced and EMPEROR-Preserved Trials, presented at the American Heart Association Scientific Sessions 2023.